Encyclopedia

KLOW Blend

KLOW Blend combines KPV with the GLOW mix of GHK-Cu, BPC-157, and TB-500, marketed for recovery and inflammation. No validated combined mechanism exists in humans, none of it holds FDA approval, and evidence for the blend stays largely anecdotal. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.

Start free →Dose tools

Category	Healing / Recovery
Regulatory status	Not FDA-approved as a blend or as individual components for any human indication.

Mechanism

A combination marketed for recovery and anti-inflammatory effects: KPV (a C-terminal alpha-MSH tripeptide fragment) is reported to have anti-inflammatory activity, added to the GLOW components (GHK-Cu, BPC-157, TB-500). No validated combined mechanism in humans.

Half-life

Not established for the blend; component values are uncertain with limited human data. KPV is a small peptide with presumed short half-life; BPC-157, GHK-Cu, and TB-500 human pharmacokinetics are not well characterized.

Regulatory status

Not FDA-approved as a blend or as individual components for any human indication. Research chemical status. TB-500 (thymosin beta-4) is prohibited by WADA; BPC-157 compounding has been restricted by FDA. KPV is not an approved drug.

Safety

Same concerns as the GLOW blend: sterility and purity risks of unregulated injectables, minimal human safety data, theoretical copper accumulation. No long-term human safety data for the combination.

Evidence

Largely anecdotal for the blend; components are mostly preclinical/animal data with very limited human evidence.

Sources

Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine IBD models. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
Xiao B, et al. Orally targeted delivery of tripeptide KPV alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. https://pubmed.ncbi.nlm.nih.gov/28143741/
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018;19(7):1987. https://pubmed.ncbi.nlm.nih.gov/29986520/
Hsieh MJ, et al. Pro-angiogenic BPC157 and VEGFR2 activation. J Mol Med. 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/

PepWise is an informational and educational tracking tool, not medical advice and not a medical device. KLOW Blend may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.